Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06425549 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
A Phase 3 study of Moderate to Severe Plaque Psoriasis, sponsored by UCB Biopharma SRL.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 168
- Enrollment target
- 20
- Study locations
NCT06425549 is a Phase 3 study of Moderate to Severe Plaque Psoriasis that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 168 participants, above the 50-participant average among 3 other Moderate to Severe Plaque Psoriasis trials with a reported enrollment target (236% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT06425549, a Phase 3 study of Moderate to Severe Plaque Psoriasis, is actively recruiting participants, sponsored by UCB Biopharma SRL.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 168 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).
Conditions Studied
Interventions
- DRUG placebo
- DRUG bimekizumab
- DRUG ustekinumab
Study Locations (20)
Other
- Ps0021 40121 - Brussels
- Ps0021 40420 - Liège
- Ps0021 50618 - Mississauga
- Ps0021 50357 - St. John's
- Ps0021 50617 - St. John's
- Ps0021 40748 - Plzen-bory
- Ps0021 40742 - Argenteuil
- Ps0021 40754 - Nantes
- Ps0021 40740 - Bad Bentheim
- Ps0021 40515 - Berlin
- Ps0021 40138 - Bonn
California
- Ps0021 50162 - Fountain Valley
- Ps0021 50161 - Los Angeles
- Ps0021 50196 - Northridge
Texas
- Ps0021 50201 - Arlington
- Ps0021 50355 - Dallas
Florida
- Ps0021 50581 - Miami
Indiana
- Ps0021 50344 - Indianapolis
New York
- Ps0021 50599 - Kew Gardens
South Carolina
- Ps0021 50084 - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2024-06-25 |
| Est. Completion | 2030-11-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06425549
The ClinicalTrials.gov registry entry for NCT06425549 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 50-participant average among 3 other Moderate to Severe Plaque Psoriasis trials with a reported enrollment target (236% higher). The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate to Severe Plaque Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT06425549 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Texas.
Frequently Asked Questions
What is clinical trial NCT06425549 about?
NCT06425549 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis". The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).
What is the current status of trial NCT06425549?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 168 participants. The study started on 2024-06-25. Estimated completion is 2030-11-08.
What conditions does trial NCT06425549 study?
This clinical trial studies the following conditions: Moderate to Severe Plaque Psoriasis.
What interventions are being tested in trial NCT06425549?
The interventions under investigation include: placebo (DRUG), bimekizumab (DRUG), ustekinumab (DRUG).
Who is sponsoring clinical trial NCT06425549?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06425549 being conducted?
This trial has 20 study locations across California, Florida, Indiana, New York, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate to Severe Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.